Editor - Sijumon Kunjachan | Harvard Medical School | 21329
ISSN: 2167-065X

Clinical Pharmacology & Biopharmaceutics
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Sijumon Kunjachan

Sijumon Kunjachan
Sijumon Kunjachan
Postdoctoral Research Scientist
Department of Radiation Oncology
Brigham and Women’s Hospital
Dana-Farber Cancer Institute
Harvard Medical School
Harvard Medical School


Dr. Sijumon Kunjachan received his PhD in cancer nanomedicine from RWTH University in 2013. Currently, he is working at the Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School. At present, his research focuses on the development and evaluation of nanomedicines for the drug delivery, imaging and radiation therapy for the treatment of cancer. Dr. Kunjachan is particularly well-known for his original exciting research on 'passive versus active tumor targeting using polymeric nanomedicines' and ‘gold nanoparticles for radiation therapy’. Based on his previous work, he has received several awards and honors, such as Radiation Research travel award, World Molecular Imaging poster prize and Elsevier Reviewer Recognition award, to name a few. He is serving as an expert reviewer for over 15 international journals including Biomaterials, Journal of Controlled Release, Biomacromolecules, Pharmaceutical Research, International Journal of Pharmaceutics, Drug Design, Development and Therapy, Clinical Pharmacology & Biopharmaceutics, Nanotechnology: Science and Applications, Clinical Pharmacology, Journal of Antimicrobial Chemotherapy, International Journal of Nanomedicine, Pharmaceutical Nanotechnology, Journal of Nuclear Medicine and Therapy and several others. Dr. Kunjachan has co-authored a book chapter titled 'Nanotheranostics' in Nanotechnology and Drug Delivery, Volume 2- Nano-Engineering Strategies and Nanomedicines against Severe Diseases. A senior scholar member in Radiation Research Society (RadRes), American Chemical Society (ACS), European Society of Molecular imaging (ESMI) and several other professional organizations. Dr. Kunjachan also serves as a reviewer for several scientific grants/ fundings including the EU scientific trans-domain proposals and the National Research, Development and Innovation Office (NKFIH) of the Hungarian Academy of Sciences.

Research Interest

Development and evaluation of nanomedicines for the drug delivery, imaging and radiation therapy for the treatment of cancer